Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Down 24.7% in December

Adaptimmune Therapeutics plc (NASDAQ:ADAP) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 5,060,000 shares, a decline of 24.7% from the November 30th total of 6,720,000 shares. Based on an average daily volume of 1,840,000 shares, the short-interest ratio is currently 2.8 days.

Wall Street Analyst Weigh In

A number of brokerages have commented on ADAP. Mizuho decreased their price objective on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a research report on Wednesday, November 27th. StockNews.com lowered Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. HC Wainwright lowered their price objective on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a research report on Thursday, November 14th. Finally, Guggenheim cut their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Adaptimmune Therapeutics has a consensus rating of “Buy” and a consensus target price of $2.79.

Hedge Funds Weigh In On Adaptimmune Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fullcircle Wealth LLC bought a new stake in shares of Adaptimmune Therapeutics in the 3rd quarter valued at about $33,000. Vontobel Holding Ltd. increased its stake in Adaptimmune Therapeutics by 230.8% in the third quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 30,000 shares in the last quarter. GSA Capital Partners LLP bought a new stake in Adaptimmune Therapeutics in the third quarter valued at approximately $95,000. Virtu Financial LLC raised its holdings in Adaptimmune Therapeutics by 27.5% in the third quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 21,769 shares during the period. Finally, Jane Street Group LLC boosted its position in shares of Adaptimmune Therapeutics by 130.4% during the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 98,581 shares in the last quarter. Institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Trading Down 2.3 %

Shares of NASDAQ:ADAP traded down $0.01 during midday trading on Monday, hitting $0.58. The company had a trading volume of 302,770 shares, compared to its average volume of 1,786,886. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. Adaptimmune Therapeutics has a 12 month low of $0.55 and a 12 month high of $2.05. The firm has a fifty day simple moving average of $0.69 and a 200 day simple moving average of $0.94. The stock has a market cap of $147.49 million, a price-to-earnings ratio of -2.62 and a beta of 2.18.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.